Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial

@inproceedings{BeltrnGonzlez2021EfficacyAS,
  title={Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial},
  author={J. Beltr{\'a}n-Gonz{\'a}lez and M. Gonz{\'a}lez-G{\'a}mez and E.-A. Mendoza-Enciso and R. J. Esparza-Maldonado and D. Hernanez-Palacios and S. Duenas-Campos and I. Ovalle-Robles and M. J. Macias-Guzman and A. G. Garcia Diaz and C. M. Gutierrez Pena and L. Martinez-Medina and V. M. Monroy Colin and J. M. Arreola Guerra},
  booktitle={medRxiv},
  year={2021}
}
Background In the search for active drugs against COVID19, the indications of many have been redirected. Ivermectin and Hydroxychloroquine are drugs that inhibit viral replication in vitro and that have been used in several medical centers. Objectives: This clinical trial analyzes the efficacy of Ivermectin and Hydroxychloroquine in patients with moderate COVID19 and in need of hospitalization. Methods. This a controlled, clinical, randomized, double blind trial that included patients with… Expand
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
BACKGROUND Hydroxychloroquine (HCQ) is an anti-malarial and immunomodulatory drug considered a potential candidate for drug repurposing in COVID-19 due to their in vitro antiviral activity againstExpand
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials
BACKGROUND Hydroxychloroquine (HCQ) is an anti-malarial and immunomodulatory drug considered a potential candidate for drug repurposing in COVID-19 due to their in vitro antiviral activity againstExpand
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Abstract Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysisExpand
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
TLDR
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin, and the apparent safety and low cost suggest that iverMectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally. Expand
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials
TLDR
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease, and IVM is not a viable option to treat patients. Expand
Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials
TLDR
Hydroxychloroquine use was not associated with mortality in COVID-19 patients in pooling results from RCTs, but it was associated with 20% mortality reduction when findings from observational studies were combined (low level of certainty of evidence). Expand
Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials
TLDR
Ivermectin was associated with decreased mortality in COVID-19 with a low certainty of evidence and adequately powered double-blinded placebo-controlled RCTs are required for definite conclusion. Expand
Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19
  • C. S. Kow, Syed S. Hasan
  • Medicine
  • American journal of therapeutics
  • 2021
To the Editor: Since the outbreak of coronavirus disease 2019 (COVID-19), morbidity and mortality continue to increase worldwide.1 Several drugs have been developed/repurposed for the treatment ofExpand
Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies
TLDR
The study suggests that ivermectin may offer beneficial effects towards Covid‐19 outcomes, and more randomized clinical trial studies are still needed to confirm the results. Expand
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
TLDR
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease, and is not a viable option to treat patients. Expand
...
1
2
...

References

SHOWING 1-10 OF 20 REFERENCES
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
TLDR
Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. Expand
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
TLDR
Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement, and Randomized controlled trials are needed to confirm these findings. Expand
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
TLDR
In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Expand
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
TLDR
These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. Expand
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
TLDR
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. Expand
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
TLDR
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid -19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. Expand
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19
TLDR
The likelihood of a successful clinical trial using the approved dose of ivermectin is low and combination therapy should be evaluated in vitro. Expand
Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines
TLDR
An expert consensus statement on the prophylaxis and management of VTE associated with COVID-19 is developed and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. Expand
Effects of chloroquine on viral infections: an old drug against today's diseases
TLDR
The available information on the effects of chloroquine on viral infections is reviewed, raising the question of whether this old drug may experience a revival in the clinical management of viral diseases such as AIDS and severe acute respiratory syndrome. Expand
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
TLDR
Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection able to effect ~5000-fold reduction in viral RNA at 48 h. Expand
...
1
2
...